منابع مشابه
Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
© 2016 Harborside Press® Acute lymphoblastic leukemia (ALL) is a rare form of leukemia, with an estimated 6,250 new cases diagnosed in the United States in 2015 and approximately 1,450 deaths (American Cancer Society, 2015). With current available induction therapies, complete remission (CR) rates in adults are approximately 75% to 90% (Faderl et al., 2010; Bassan & Hoelzer, 2011). After induct...
متن کاملBone Scintigraphy in Acute Lymphoblastic Leukemia
Leukemia is the most common childhood cancer and accounts for 30-40% of all malignancies. A retrospective review was performed of the hospital records of 9 children, 6 boys and 3 girls, aged from 2.5 to 15 years with ALL initially referred to Nemazee hospital Nuclear medicine center for whole body bone scanning between 2000 and 2002. Bone marrow pathology established ALL (L1) in two and ALL (...
متن کاملPhase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled children < 18 years old with relapsed/refractory...
متن کاملClinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Despite advances in current management, patients continue to have poo...
متن کاملProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Anticancer Therapy
سال: 2016
ISSN: 1473-7140,1744-8328
DOI: 10.1586/14737140.2016.1143778